Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Compare
Compare
Traded in other countries / regions
VYGR.USAVT6.GermanyVYGR.Mexico IPO Date
2015-11-18Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.62 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 3.21 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.54 | |||||
| Beneish M-Score | 2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7 | |||||
| 3-Year EBITDA Growth Rate | 50.3 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year Book Growth Rate | 9.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | -29.38 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.53 | |||||
| 9-Day RSI | 42.59 | |||||
| 14-Day RSI | 43.73 | |||||
| 6-1 Month Momentum % | -16.04 | |||||
| 12-1 Month Momentum % | 0.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.45 | |||||
| Quick Ratio | 8.45 | |||||
| Cash Ratio | 7.81 | |||||
| Days Sales Outstanding | 45.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | -41.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 5.54 | |||||
| Net Margin % | 15.8 | |||||
| FCF Margin % | -17.34 | |||||
| ROE % | 9.12 | |||||
| ROA % | 6.54 | |||||
| ROIC % | 8.98 | |||||
| ROC (Joel Greenblatt) % | 18.72 | |||||
| ROCE % | 2.68 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.89 | |||||
| PE Ratio without NRI | 8.89 | |||||
| PS Ratio | 1.89 | |||||
| PB Ratio | 0.95 | |||||
| Price-to-Tangible-Book | 0.95 | |||||
| EV-to-EBIT | 1.73 | |||||
| EV-to-EBITDA | 1.11 | |||||
| EV-to-Forward-EBITDA | -0.13 | |||||
| EV-to-Revenue | 0.1 | |||||
| EV-to-Forward-Revenue | 0.2 | |||||
| EV-to-FCF | -0.55 | |||||
| Price-to-Projected-FCF | 3.51 | |||||
| Price-to-Graham-Number | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 1.14 | |||||
| Price-to-Net-Cash | 1.26 | |||||
| Earnings Yield (Greenblatt) % | 57.8 | |||||
| FCF Yield % | -9.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 150.21 | ||
| EPS (TTM) (€) | 0.596 | ||
| Beta | 0.44 | ||
| Volatility % | 72.44 | ||
| 14-Day RSI | 43.73 | ||
| 14-Day ATR (€) | 0.240358 | ||
| 20-Day SMA (€) | 5.87825 | ||
| 12-1 Month Momentum % | 0.82 | ||
| 52-Week Range (€) | 5.01 - 10.1 | ||
| Shares Outstanding (Mil) | 54.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Voyager Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(FRA:VT6)'s stock price today?
The current price of FRA:VT6 is €5.41. The 52 week high of FRA:VT6 is €10.10 and 52 week low is €5.01.
When is next earnings date of Voyager Therapeutics Inc(FRA:VT6)?
The next earnings date of Voyager Therapeutics Inc(FRA:VT6) is 2025-02-28 Est..
Does Voyager Therapeutics Inc(FRA:VT6) pay dividends? If so, how much?
Voyager Therapeutics Inc(FRA:VT6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers